These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 15133849

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Effect of Telbivudine Tablet Combined Jianpi Bushen Recipe on HBV Specific Cytotoxic T Lymphocyte and HBeAg Seroconversion in Patients with HBeAg Positive Chronic Hepatitis B].
    Hua Z, Xu W, Fu DC, Li YG, Guo XY, Tu KW, Dai YP.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 May; 36(5):530-4. PubMed ID: 27386641
    [Abstract] [Full Text] [Related]

  • 24. [Observation on effect of yugan granule in treating patients of chronic hepatitis B with basic core promoter mutant hepatitis B virus].
    Xie CL, Shao ZY.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2002 Jul; 22(7):502-4. PubMed ID: 12592682
    [Abstract] [Full Text] [Related]

  • 25. [Effect of kurarinol on peripheral blood CTL surface PD-1 expression of patients with chronic hepatitis B].
    Zhu YF, Gu XB, Yang XJ, Hua Z, Lu ZH, Zang B, Wu HY, Jiang YM, Chen HK, Pei H, Xu YQ.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Dec; 26(6):446-9. PubMed ID: 23627026
    [Abstract] [Full Text] [Related]

  • 26. [Effect of Shuganlipi decoction on Th1/Th2 cytokines in patients with chronic hepatitis B].
    Jiang SS, He ST, Han YM, Xia AM, Wang HM.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Nov; 30(11):2449-51. PubMed ID: 21097402
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Difference and significance of peripheral blood T-lymphocyte subsets in patients with chronic hepatitis B and asymptomatic HBV carriers].
    Tian Y, Qiu ZF, Li TS.
    Zhonghua Yi Xue Za Zhi; 2005 Dec 14; 85(47):3354-8. PubMed ID: 16409844
    [Abstract] [Full Text] [Related]

  • 29. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
    Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, Brett S, Chokshi S, Naoumov NV.
    Hepatology; 2008 Sep 14; 48(3):759-69. PubMed ID: 18697210
    [Abstract] [Full Text] [Related]

  • 30. Effect of oxymatrine on specific cytotoxic T lymphocyte surface programmed death receptor-1 expression in patients with chronic hepatitis B.
    Gu XB, Yang XJ, Hua Z, Lu ZH, Zhang B, Zhu YF, Wu HY, Jiang YM, Chen HK, Pei H.
    Chin Med J (Engl); 2012 Apr 14; 125(8):1434-8. PubMed ID: 22613649
    [Abstract] [Full Text] [Related]

  • 31. [Clinical study on effect of ganneng dripping pill in treating chronic hepatitis B].
    Li L, Yuan HL, Wu Q.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2006 Sep 14; 26(9):788-90. PubMed ID: 17058826
    [Abstract] [Full Text] [Related]

  • 32. [Effect of bushen recipe on the immune effector molecules of natural killer cells in patients with chronic hepatitis B].
    Gao YQ, Yao Y, Li M.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Jul 14; 30(7):710-3. PubMed ID: 20929127
    [Abstract] [Full Text] [Related]

  • 33. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W, Yuan H, Mao XR, Deng YD, Chen L.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar 14; 21(3):184-8. PubMed ID: 23967738
    [Abstract] [Full Text] [Related]

  • 34. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
    Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J, Giannousis J, Bilalis A, Kafiri G, Tzourmakliotis D, Archimandritis AJ.
    Hepatology; 2008 Nov 14; 48(5):1451-9. PubMed ID: 18924246
    [Abstract] [Full Text] [Related]

  • 35. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ, Li SG, Wen FY, Yang XY, Wu JL, Tan B, Fu J.
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug 14; 17(8):564-8. PubMed ID: 19719911
    [Abstract] [Full Text] [Related]

  • 36. The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b.
    Gu J, Sun R, Shen S, Yu Z.
    Pak J Pharm Sci; 2015 Jul 14; 28(4 Suppl):1493-7. PubMed ID: 26431662
    [Abstract] [Full Text] [Related]

  • 37. Peripheral blood lymphocyte dynamics and viral kinetics in patients with chronic active hepatitis B virus infection treated by tenofovir.
    Arasli M, Ustundag Y, Delikanli B, Harmandar F, Buyukuysal C.
    Hepatogastroenterology; 2012 May 14; 59(115):851-7. PubMed ID: 22193343
    [Abstract] [Full Text] [Related]

  • 38. Influence of Treg cells and HBV genotype on sustained response and drug resistance in the treatment with nucleoside drugs.
    Zhang YR, Li B, Wang CX, Zhou N, Qi W, Li XL, Wu LY, Wei SF, Zhang YD.
    Braz J Med Biol Res; 2017 Mar 02; 50(3):e5796. PubMed ID: 28273209
    [Abstract] [Full Text] [Related]

  • 39. [Differential liver histopathological features of chronic HBV infection patients with normal and mildly elevated serum ALT].
    Ying RS, Yang Z, Chen YY, Yang KL, Xiao YH, Wu LJ, Fan HM.
    Zhonghua Gan Zang Bing Za Zhi; 2012 Aug 02; 20(8):585-8. PubMed ID: 23207151
    [Abstract] [Full Text] [Related]

  • 40. [Influence of a triplex superimposed treatment on HBV replication and mutation during treating chronic hepatitis B].
    Wu L, Liu H, Xue P, Lu ZG, Du KF.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Sep 02; 15(3):236-8. PubMed ID: 11986694
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.